Prolonged chronic phase of greater than 10 years of chronic myelogenous leukemia in a patient with congenital human immunodefeciency virus infection
Author(s) -
Setty Bhuvana A.,
Hayani Karen C.,
Sharon Bruce I.,
Schmidt Mary Lou
Publication year - 2009
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22096
Subject(s) - medicine , chronic myelogenous leukemia , lamivudine , nelfinavir , imatinib , zidovudine , philadelphia chromosome , imatinib mesylate , leukemia , dasatinib , alpha interferon , virus , pediatrics , interferon , immunology , viral load , viral disease , myeloid leukemia , antiretroviral therapy , chromosomal translocation , hepatitis b virus , biochemistry , chemistry , gene
Abstract A 15‐year‐old male with congenital HIV infection was diagnosed with chronic myelogenous leukemia (CML) at age 4 years 9 months. HIV was initially treated with zidovudine. For the last >10 years he has received didanosine, lamivudine, and nelfinavir. CML was treated with Interferon alfa (INF‐α) for >10 years and a brief course of hydroxyurea (HU). He remained in chronic phase CML since diagnosis however recent molecular monitoring revealed increased BCR/ABL transcripts necessitating a change in therapy to imatinib. The very prolonged chronic phase of CML in this patient has been unexpected especially in light of the underlying congenital HIV infection. Pediatr Blood Cancer 2009;53:658–660. © 2009 Wiley‐Liss, Inc.